Asahi Kasei Pharma & Alchemedicine launch first human trials for hard-to-treat diseases drugs

STADA & Bio-Thera bag European nod for Gotenfia

OneSource bags SFDA nod for generic Ozempic in Saudi Arabia

India’s go-to diabetes test under scrutiny as new evidence flags major gaps

The paper highlights how conditions common across India—including anemia, inherited hemoglobin disorders, and glucose-6-phosphate dehydrogenase (G6PD) deficiency—can significantly distort HbA1c readings

AstraZeneca expands obesity and diabetes pipeline with $1.2B CSPC deal

CSPC will receive an upfront $1.2 billion from AstraZeneca for access to eight programmes, AI molecular design capabilities, and the LiquidGel platform

Siegfried expands US footprint with major acquisition of Noramco & Extractas Bioscience

The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio

Siegfried expands US footprint with major acquisition of Noramco & Extractas Bioscience

Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites

Ionis and Otsuka score EU nod for DAWNZERA, offering new hope for rare HAE patients

The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe

Functional Gut Clinic launches UK’s first boutique GI clinical trials division

Gastrointestinal conditions affect millions across the UK, yet research in the field has often been fragmented, slow, or under-resourced

Alteogen strikes $285M deal with GSK subsidiary for innovative cancer drug delivery

This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market